Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 13/20 | 0.55 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pnu-22394 SCHEMBL29388570 | 1.00 | HTR2C (1.00) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Pnu-22394 SCHEMBL29779480 | 0.98 | KDM4E (1.00) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL30704389 | 0.88 | HTR2A (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL4131362 | 0.88 | HTR2A (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL967629 | 0.88 | HTR2C (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL31078590 | 0.87 | KDM4E (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL9057430 | 0.87 | KDM4E (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL30396890 | 0.87 | KDM4E (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL844491 | 0.80 | HTR2A (0.67) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL30223611 | 0.80 | HTR2A (0.67) | HTR2CHTR2AKDM4EALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | SATO PHARMACEUTICAL CO., LTD. (JP) | 2022-08-11 | — | — | US | claimed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| WO-2014195695-A1 | THERAPEUTIC COMBINATIONS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-12-11 | — | — | WO | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | disclosed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | disclosed |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | SATO PHARMACEUTICAL CO., LTD. (JP) | 2022-08-11 | — | — | US | disclosed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| US-7291738-B2 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1792629-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-20030181485-A1 | A (2-methyl-3-pyridinyl)oxy)-3-pyridinyl)urea derivatives for treatment of a disease or disorder of the central nervous system, medical diagnosis | PHARMACIA & UPJOHN COMPANY | 2003-09-25 | — | — | US | disclosed |
| EP-0910567-A1 | TRICYCLIC IBOGAINE ANALOGS, THEIR PREPARATION AND THEIR USE IN TREATING SUBSTANCE ABUSE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997020847-A1 | TRICYCLIC IBOGAINE ANALOGS, THEIR PREPARATION AND THEIR USE IN TREATING SUBSTANCE ABUSE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1997-06-12 | — | — | WO | disclosed |
| US-5616575-A | COCAINE ADDICTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | MUSK, MYLK2, MYH2 | HTR2C 72/4885HTR2A 28/4885KDM4E 1326/4885 |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | HTR2C, HTR5A, HTR1A | HTR2C 1/4885HTR2A 5/4885KDM4E 2994/4885 |
| US-20030181485-A1 | A (2-methyl-3-pyridinyl)oxy)-3-pyridinyl)urea derivatives for treatment of a disease or disorder of the central nervous system, medical diagnosis | PMP22, TPMT, PNPO | HTR2C 180/4885HTR2A 589/4885KDM4E 1172/4885 |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | ADRA2C, HTR2C, HTR3A | HTR2C 2/4885HTR2A 5/4885KDM4E 4168/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | HTR2C 1/4885HTR2A 4/4885KDM4E 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.